Biotech | April 10, 2022
LivaNova initiates targeted commercial launch of Essenz patient monitor
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Subscribe To Our Newsletter & Stay Updated
